...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

AMSilk Achieves Large-scale Production Validation for Spidersilk® and Hires New CBO

| Print |
Tuesday, 30 October 2012 08:00 (UTC + 1)

amsilk_logo

Planegg, Germany, and Boston, USA, October 30, 2012 / B3C newswire / - AMSilk® achieved a large-scale production validation after a technical test campaign for the production of recombinant spider silk proteins (“Spidersilk®”). Spidersilk can now be manufactured at any available scale in the industry. This is a critical achievement in enabling the production of Spidersilk from the kilogram to the metric ton scale. 

“We have clearly demonstrated that Spidersilk can be manufactured with a large-scale and economical, environmentally friendly process,” says Axel Leimer, CEO of AMSilk.
“With this we have laid the foundation for many technical products and high performance fibers made from our recombinant spider silk proteins.” 

AMSilk develops processes in house and outsources manufacturing with a custom manufacturer for industrial-scale production. 

“On this day we also welcome Mr. Mathias Woker to our team as our Chief Business Officer, says Axel Leimer. “Mr. Woker has extensive global experience in business development and licensing as well as product marketing in German and US-based enterprises. His role is important in translating our technology lead into business opportunities.” 

Mr. Woker stated: “I am excited to join AMSilk at this important time in its growth and development toward a product- and market-driven enterprise.” 

Mathias Woker has previously led the business development and licensing efforts of profitable biotech companies in Germany and the US and worked in a US-based strategic management consulting firm. Mr. Woker will be located in Boston, Massachusetts, and will head the US expansion of AMSilk.

 
About AMSilk
Spider silk has attracted man’s interest for thousands of years, mainly due to its toughness and elasticity. The silk is biocompatible and can be used in formulations for specialized coatings, films, nonwovens and in pharmaceuticals. As with most biomaterials, spider silk has evolved over millions of years resulting in a combination of properties that far exceeds any man-made material. AMSilk has developed a proprietary process for producing biopolymers such as spider silk on an industrial scale. Tailor-made materials using the AMSilk®-Technology enable new and superior products with previously unachievable features, spanning multiple industries and applications. AMSilk was founded in 2008 and is located at the IZB in Planegg near Munich. AMSilk’s investors are MIG Funds and AT Newtec, Munich. Projects are partially funded through grants from the German Federal Ministry of Education and Research and the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology with project management provided by the PTJ and VDI. For more information visit our website at www.amsilk.com. 

AMSilk and Spidersilk are registered trademarks in the European Union and trademark applications in the USA of AMSilk GmbH, Germany.

 
Contact for Europe and Asia/Pacific:

Axel H. Leimer
Managing Director
AMSilk GmbH
Am Klopferspitz 19 im IZB
82152 Planegg/Martinsried, Germany
Tel: +49 (0)89 38156-4430
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Contact for the Americas:

Mathias U. Woker
Chief Business Officer
AMSilk GmbH
Tel:  +1 (781) 864-5868
This e-mail address is being protected from spambots. You need JavaScript enabled to view it